Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 49
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Womens Health ; 21(1): 153, 2021 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-33858396

RESUMEN

BACKGROUND: Low back pain during pregnancy and postpartum is common and might not arouse clinical interest. Pregnancy-associated breast cancer is often found as a breast mass, but its diagnosis is difficult during pregnancy and postpartum. As more women delay their first pregnancies, its incidence may increase in the future. CASE PRESENTATION: The patient was a 30-year-old gravida 3, para 3. She had low back pain from the second trimester of her previous two pregnancies, which improved spontaneously after delivery. In her third pregnancy, she again developed low back pain in the second trimester. Her delivery was normal. However, her low back pain continued for up to 7 months postpartum and then worsened sharply. A whole-body scan revealed a compression fracture due to multiple spinal metastases of breast cancer. As she had not complained about her breasts, they had not been closely examined. CONCLUSIONS: This case shows the importance of considering bone metastases from breast cancer in the differential diagnosis of patients with low back pain during pregnancy and postpartum.


Asunto(s)
Neoplasias de la Mama , Dolor de la Región Lumbar , Complicaciones del Embarazo , Fracturas de la Columna Vertebral , Adulto , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/diagnóstico , Femenino , Humanos , Dolor de la Región Lumbar/etiología , Periodo Posparto , Embarazo , Complicaciones del Embarazo/diagnóstico
2.
J Obstet Gynaecol Res ; 47(4): 1388-1396, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33559219

RESUMEN

AIM: The aim is to examine the prevalence of low bone mineral density (BMD) (osteoporosis and osteopenia) of lumbar and femoral bones in puerperal women for the prenatal and postnatal care to ensure their optimal bone health. METHODS: We analyzed the first scan data of 1079 Japanese puerperal women without bone fracture (mean age 33.5 ± 4.5 years) who had undergone deliveries at Niigata City General Hospital for 10 years. We measured BMDs of the lumbar spine [LS], femoral neck [FN], and total hip [TH] with dual-energy X-ray absorptiometry (DXA) within 30 days after delivery. RESULTS: The rates of osteoporosis of LS, FN, TH, and comprehensive diagnosis (CD) were 0.6%, 4.8%, 1.5%, and 5.4%, respectively, and osteopenia were 20.2%, 39.5%, 29.3%, and 44.3%, respectively. The multivariable-adjusted odds ratio (OR) for body mass index (BMI) before pregnancy reflected significant decreases in risk for low BMD with an OR of 0.78 (95% CI: 0.74-0.82) with the 1 kg/m2 increases. In lean women (BMI < 18.5), 71% of them had low BMD. CONCLUSIONS: Approximately 50% of puerperal women had low BMD without bone fracture. BMD measurements at puerperium, especially for lean women, may be very useful for identifying at risk of osteoporosis in future.


Asunto(s)
Enfermedades Óseas Metabólicas , Osteoporosis , Periodo Posparto , Adulto , Densidad Ósea , Enfermedades Óseas Metabólicas/diagnóstico por imagen , Enfermedades Óseas Metabólicas/epidemiología , Femenino , Humanos , Japón/epidemiología , Vértebras Lumbares , Osteoporosis/diagnóstico por imagen , Osteoporosis/epidemiología , Prevalencia
3.
Am J Perinatol ; 38(10): 1096-1102, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-32120423

RESUMEN

OBJECTIVE: We previously reported that hypertensive disorder of pregnancy (HDP) was a risk factor for hypertension and hypercholesterolemia in later life. Additionally, the age-adjusted odds ratio (OR) of HDP was 2.72 for Japanese women whose mothers had a history of HDP versus those whose mothers did not. This study aimed to clarify the association of HDP with birth weight and gestational age. STUDY DESIGN: A self-administered baseline survey of the Japanese Nurses' Health Study (JNHS) cohort was conducted from 2001 to 2007. Data on 17,278 parous female nurses who knew their own birth weights were extracted from the JNHS baseline survey (n = 49,927) and subjected to cross-sectional, retrospective analysis. Data on weeks of gestation, birth weight, and history of HDP were collected. RESULTS: The age-adjusted ORs for HDP were 1.62 (95% confidence interval [CI]: 1.20-2.19) for birth weight <2,000 g, 1.24 (CI: 1.04-1.48) for 2,000 to 2,499 g, 1.11 (CI: 1.00-1.23) for 2,500 to 2,999 g, and 1.08 (CI: 0.94-1.24) for ≥3,500 g compared with 3,000 to 3,499 g. The age-adjusted ORs for HDP were 1.27 (95% CI: 1.04-1.54) for a gestational age < 37 weeks and 0.93 (0.70-1.23) for ≥42 weeks compared with 37-41 weeks. The age-adjusted OR of the birth weight score for HDP in later life was 0.98 (CI: 0.94-1.03; Cochran-Armitage trend test: z = 0.401, p = 0.688). CONCLUSION: Among women in Japan, a history of low birth weight and prematurity are risk factors for HDP in later life. The risk of HDP among women born with low birth weight and/or premature deserves attention.


Asunto(s)
Peso al Nacer , Hipertensión Inducida en el Embarazo/epidemiología , Hipertensión/epidemiología , Madres , Nacimiento Prematuro/epidemiología , Adulto , Estudios Transversales , Femenino , Edad Gestacional , Humanos , Japón/epidemiología , Modelos Logísticos , Persona de Mediana Edad , Embarazo , Estudios Retrospectivos , Factores de Riesgo
4.
J Obstet Gynaecol Res ; 45(4): 766-786, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30675969

RESUMEN

Six years after the first edition of The Guideline for Gynecological Practice, which was jointly edited by The Japan Society of Obstetrics and Gynecology and The Japan Association of Obstetricians and Gynecologists, the third revised edition was published in 2017. The 2017 Guidelines includes 10 additional clinical questions (CQ), which brings the total to 95 CQ (12 on infectious disease, 28 on oncology and benign tumors, 27 on endocrinology and infertility and 28 on healthcare for women). Currently a consensus has been reached on the Guidelines and therefore the objective of this report is to present the general policies regarding diagnostic and treatment methods used in standard gynecological outpatient care that are considered appropriate. At the end of each answer, the corresponding recommendation level (A, B, C) is indicated.


Asunto(s)
Atención Ambulatoria/normas , Enfermedades de los Genitales Femeninos/diagnóstico , Enfermedades de los Genitales Femeninos/terapia , Ginecología/normas , Guías de Práctica Clínica como Asunto/normas , Femenino , Humanos , Japón , Obstetricia/normas , Sociedades Médicas/normas
5.
Clin Calcium ; 29(1): 39-45, 2019.
Artículo en Japonés | MEDLINE | ID: mdl-30590358

RESUMEN

Post-pregnancy osteoporosis is a rare condition with little known pathophysiology. Most cases are diagnosed in the late stage of pregnancy or in the post partum while breastfeeding, particularly in first pregnancy. Non-traumatic vertebral fragility fractures are most commonly observed and characterized by prolonged severe pain and functional limitations. Conventional radiography will confirm the fracture in most cases, and magnetic resonance, which can be safely used during pregnancy, is effective in detecting vertebral fractures and bone marrow edema. It is important to exclude secondary osteoporosis, e.g. endocrine diseases, chronic liver and kidney diseases, autoimmune diseases, genetic diseases, drugs and malignant tumors. The prevalence of post-pregnancy osteoporosis is unknown, and may be estimated more than 3 for every ten thousand pregnant women. The pathophysiology of post-pregnancy osteoporosis is also unknown. The physiological bone resorption during reproduction does not normally cause fracture;instead, women who do fracture may be more likely to have additional secondary causes of bone loss and fragility, e.g. low body weight, low peak bone mass, malnutrition and heredity.


Asunto(s)
Osteoporosis , Fracturas de la Columna Vertebral , Femenino , Humanos , Osteoporosis/epidemiología , Osteoporosis/fisiopatología , Periodo Posparto , Embarazo , Radiografía , Fracturas de la Columna Vertebral/epidemiología , Fracturas de la Columna Vertebral/fisiopatología
6.
J Obstet Gynaecol Res ; 44(8): 1355-1368, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29957860

RESUMEN

Hormone replacement therapy (HRT) plays a large part in maintaining and improving the quality of life (QOL) of postmenopausal women. Despite this obvious role, the use of HRT has stagnated in Japan as well as the United States, since the interim report of the HRT trial of Women's Health Initiative study was published in 2002. The Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women's Health formulated the Guidelines for Hormone Replacement Therapy in 2009, which was subsequently revised in 2012, with the aim of organizing perceptions about HRT and allowing people to provide or receive HRT with a sense of security. Later on, in light of changes in indications for HRT and attitudes toward its impact on cancer risks, amendments were made again in 2017. With the establishment of the 2017 guidelines, practitioners in Japan are able to address various issues related to HRT with more appropriate judgment. Moreover, the practice of reliable, safe and effective HRT is expected to promote further efforts toward improvement or maintenance of QOL in patients.


Asunto(s)
Terapia de Reemplazo de Estrógeno/normas , Ginecología/normas , Menopausia , Obstetricia/normas , Guías de Práctica Clínica como Asunto/normas , Sociedades Médicas/normas , Humanos , Menopausia/efectos de los fármacos , Menopausia/metabolismo
7.
J Hum Genet ; 62(9): 803-808, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28446797

RESUMEN

The aim of this study was to investigate the parthenogenetic origin of fetiform teratoma by using molecular genetic studies and methylation status analyses. A fetiform teratoma was removed from a 35-year-old nulligravida woman. Genotyping of microsatellite marker loci, microarray analysis of single-nucleotide polymorphism (SNP) loci and methylation status analysis of the differentially methylated region (DMR) within the human IGF2-H19 locus were performed. Karyotypes of the host and the fetiform teratoma were 46, XX. The fetiform teratoma was homozygous at all loci and meiotic recombinations in the tumor were confirmed by SNP microarray analysis. Methylation analysis indicated that the host had both methylated and unmethylated IGF2-H19 DMR alleles, while the fetiform teratoma had unmethylated alleles only. Genetically, the fetiform teratoma had homozygous genotypes with meiotic recombination and a duplicated unmethylated host allele, indicating that it was a parthenogenetic tumor arising from a mature ovum after meiosis II. This is the first demonstration of a fetiform teratoma originating from a mature haploid ovum.


Asunto(s)
Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Neoplasias Ováricas/diagnóstico , Neoplasias Ováricas/genética , Teratoma/diagnóstico , Teratoma/genética , Adulto , Biomarcadores de Tumor , Metilación de ADN , Femenino , Sitios Genéticos , Genotipo , Haplotipos , Humanos , Repeticiones de Microsatélite , Imagen Multimodal/métodos , Neoplasias Ováricas/cirugía , Polimorfismo de Nucleótido Simple , Salpingooforectomía , Teratoma/cirugía
9.
Clin Calcium ; 27(5): 643-652, 2017.
Artículo en Japonés | MEDLINE | ID: mdl-28439052

RESUMEN

Post-pregnancy osteoporosis is a rare condition with little known pathophysiology. Most cases are diagnosed in the late stage of pregnancy or in the post-partum while breastfeeding, particularly in first pregnancy. Vertebral fractures are most commonly observed and characterized by prolonged severe pain and functional limitations. Measurements of bone mineral density(BMD)of the lumbar spine and proximal femur with dual energy X-ray absorptiometry(DXA)are the clinical methods most commonly used for no fracture women. Conventional radiography will confirm the fracture in most cases, and magnetic resonance(MR), which can be safely used during pregnancy, is effective in detecting vertebral fractures and bone marrow edema. Although the bone resorption increased at the end of pregnancy and lactation, the bone formation increases and the bone structure is almost recovered after cessation of lactating in postpartum. There is much uncertainty about whether pharmacological treatments should be used for osteoporosis that presents during pregnancy and lactation. This is partly because of the lack of a firm evidence base for treatment and also because there is a spontaneous recovery of bone mass and strength after pregnancy or weaning.


Asunto(s)
Densidad Ósea , Calcio/metabolismo , Osteoporosis/metabolismo , Periodo Posparto , Biomarcadores/sangre , Femenino , Humanos , Osteocitos/metabolismo , Osteoporosis/diagnóstico , Osteoporosis/tratamiento farmacológico
10.
Gynecol Endocrinol ; 31(8): 643-6, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26291801

RESUMEN

To evaluate the outcomes of patients treated with cyclic administration of dienogest after ovarian endometriotic cystectomy, following the completion of treatment. We retrospectively evaluated 26 patients treated with dienogest (2 mg/day) after cystectomy (revised American Society for Reproductive Medicine [r-ASRM] stage III-IV) in a pilot study. Dienogest was administered cyclically, for a total of six cycles, each comprising three weeks on and one week off. Outcomes of interest included severity of menstrual pain and recurrence of cysts at baseline, during the immediate post-treatment period and at the final outpatient follow-up. The mean outpatient follow-up period was 45.0 months. The visual analog scale score for menstrual pain following 6 cycles of dienogest treatment was significantly lower than that at baseline; it remained low at the final follow-up. The recurrence rates of cysts were 4% and 21% at 24 and 48 months after the completion of dienogest treatment, respectively. Six patients with recurrent disease were all classified as having r-ASRM stage IV. Our results suggest that cyclic dienogest for six months after cystectomy could relieve menstrual pain and reduce the recurrence of cysts, for approximately four years. The necessary treatment period for patients with r-ASRM stage IV disease requires further study.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Nandrolona/análogos & derivados , Quistes Ováricos/cirugía , Dolor Pélvico/prevención & control , Adulto , Antineoplásicos Hormonales/administración & dosificación , Esquema de Medicación , Femenino , Humanos , Laparoscopía , Nandrolona/administración & dosificación , Nandrolona/uso terapéutico , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
11.
Gynecol Endocrinol ; 30(11): 804-7, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25060125

RESUMEN

OBJECTIVE: This study assessed the relief of uterine bleeding and clinical symptoms during cyclic administration of dienogest for the treatment of endometriosis. METHODS: In total, 25 patients undergoing ovarian cyst enucleation and given dienogest participated in this study. Dienogest 2 mg/day was administered for 3 weeks, and the drug was then withdrawn for 1 week (cyclic administration of dienogest). This 4-week cycle was repeated six times. Patients' records were prospectively analyzed for the number of days on which any uterine bleeding occurred, as well as menstrual pain before and after the start of dienogest administration were evaluated with a view to using the data obtained herein as the basis. RESULTS: During the period of cyclic administration of dienogest, uterine bleeding occurred on 5.8 to 7.7 days per 4-week period on an average through cycles. Of uterine bleeding episodes, menstruation-like uterine bleeding was present in about 80% of patients. The visual analog scale (VAS) value for menstrual pain significantly decreased from 3.8 before dienogest administration after surgery to 1.5 at the completion of cycle 1, VAS remained low thereafter. CONCLUSION: These results raise the possibility that cyclic administration of dienogest may relieve lessen uterine bleeding, a major adverse event and menstrual pain.


Asunto(s)
Endometriosis/tratamiento farmacológico , Antagonistas de Hormonas/uso terapéutico , Nandrolona/análogos & derivados , Enfermedades del Ovario/tratamiento farmacológico , Hemorragia Uterina/tratamiento farmacológico , Adulto , Esquema de Medicación , Femenino , Antagonistas de Hormonas/administración & dosificación , Humanos , Nandrolona/administración & dosificación , Nandrolona/uso terapéutico , Resultado del Tratamiento , Adulto Joven
12.
J Obstet Gynaecol Res ; 40(2): 599-602, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24118367

RESUMEN

The effects of airbag deployment in motor vehicle accidents (MVA) on the fetus are poorly understood. A 22-year-old woman at 24 weeks of gestation collided with a telephone pole while driving. She was restrained and an airbag deployed. Although she had no major injuries, she experienced decreased fetal movements. Fetal heart rate (FHR) monitoring revealed loss of variability without any evidence of abruptio placentae, and 4 days later, the variability spontaneously recovered. Two weeks after the MVA, ultrasonography showed unilateral ventricular dilatation suggestive of fetal brain injury. Magnetic resonance imaging revealed subdural hematoma, intraventricular hemorrhage and cystic lesions, interpreted as indirect (hypoxic-ischemic) and direct (hemorrhagic) intracranial injuries. After MVA with airbag deployment, FHR monitoring can show a transient loss of variability, which may precede the appearance of fetal brain injury.


Asunto(s)
Airbags/efectos adversos , Lesiones Encefálicas/diagnóstico , Enfermedades del Sistema Nervioso/etiología , Efectos Tardíos de la Exposición Prenatal/etiología , Lesiones Prenatales/diagnóstico , Accidentes de Tránsito , Lesiones Encefálicas/etiología , Lesiones Encefálicas/fisiopatología , Preescolar , Femenino , Feto , Frecuencia Cardíaca Fetal , Humanos , Embarazo , Lesiones Prenatales/etiología , Lesiones Prenatales/fisiopatología , Adulto Joven
13.
Gynecol Oncol ; 131(3): 674-8, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24060414

RESUMEN

OBJECTIVE: Taste disturbance is known to occur as one of the adverse events associated with chemotherapy for gynecological cancer, but few studies have attempted to assess it in practical terms. Therefore, a range of taste tests was performed in gynecological cancer patients. METHODS: The patients were 23 women with gynecological cancer being treated with anticancer agents. Subjective symptoms of altered taste were classified, and objective findings were obtained with the following four gustatory tests: serum trace element (zinc, copper, iron) levels, tongue cultures, electrogustometry, and the filter paper disc tests. RESULTS: Of the 23 subjects, 11 perceived taste disturbances. The serum zinc level was consistently below the lower limit of normal. On tongue cultures, indigenous bacteria were seen in all patients during the entire treatment period. Electrogustometry revealed a tendency for the development of hypogeusia in the chorda tympani nerve field. Conversely, hypergeusia tended to develop gradually in the greater petrosal nerve field. The filter paper disc test revealed a tendency for the development of hypergeusia for sweetness, saltiness, and sourness in the chorda tympani nerve field. Hypogeusia for bitterness tended to develop with increasing number of chemotherapy cycles. The glossopharyngeal nerve field exhibited the same tendencies as observed in the chorda tympani nerve field. In the greater petrosal nerve field, there was a tendency for the development of hypergeusia for sweetness, sourness, and bitterness. CONCLUSIONS: Abnormal test results were seen in half of patients after cancer chemotherapy.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de los Genitales Femeninos/tratamiento farmacológico , Trastornos del Gusto/inducido químicamente , Trastornos del Gusto/diagnóstico , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Hidrocarburos Aromáticos con Puentes/administración & dosificación , Hidrocarburos Aromáticos con Puentes/efectos adversos , Carboplatino/administración & dosificación , Carboplatino/efectos adversos , Cobre/sangre , Femenino , Neoplasias de los Genitales Femeninos/sangre , Humanos , Hierro/sangre , Persona de Mediana Edad , Trastornos del Gusto/sangre , Taxoides/administración & dosificación , Taxoides/efectos adversos , Lengua/efectos de los fármacos , Lengua/fisiopatología , Zinc/sangre , Zinc/deficiencia
14.
Womens Midlife Health ; 8(1): 6, 2022 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-35659793

RESUMEN

BACKGROUND: Many women experience various symptoms during the period of menopausal transition, including complaints of reduced cognitive functioning. However, these complaints are not necessarily recognized as core menopausal symptoms. In this study, we sought to characterize subjective complaints of reduced cognitive functioning by analyzing cross-sectional data from the Japan Nurses' Health Study (JNHS). METHODS: The JNHS 4-year follow-up questionnaire containing a 21-item climacteric symptom checklist, which included a question about "poor memory or forgetfulness", was mailed between 2005 and 2011 to all JNHS participants, regardless of their age at the time of the survey. We estimated the prevalence of slight and severe complaints in 5-year age-groups. We used principal component analysis to explore the underlying factors among the 21 symptoms during the menopausal transition period in women aged 45-54 years at the time of the survey. We also examined risk factors for complaints using multivariable modified Poisson regression analysis. RESULTS: In total, 12,507 women responded to the 4-year survey. The mean age at the time of the 4-year survey was 46.5 years (range 27-82). "Poor memory or forgetfulness" showed a peak prevalence of 81.7% (severe 27.9%; slight 53.8%) at 50-54 years, and gradually decreased after 55 years. Principal component analysis indicated that "poor memory or forgetfulness" belonged to somatic symptoms and was close to psychological symptoms in women aged 45-54 years. In women aged 45-54 years, the complaint was also significantly associated with hot flashes and sweats. Multivariable modified Poisson regression analysis showed that menopausal status (uncertain and postmenopausal), less sleep (sleep of < 5 h and sleep of 5- < 6 h), night-shift work, and severe vasomotor symptoms (VMS) were significantly associated with the prevalence of severe complaints of reduced cognitive functioning in women aged 45-54 years. CONCLUSIONS: We found that prevalence of "poor memory or forgetfulness" was highest during the menopausal transition period and among perimenopausal women. This subjective complaint was associated with somatic, psychological complaints and VMS. It may be useful for women with cognitive problems in the transition period to consider management of comorbid menopausal symptoms.

15.
Clin Case Rep ; 10(2): e05321, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35145686

RESUMEN

This report presents an unusual case of multiple paraovarian cysts that required emergency surgery due to a paraovarian cyst being entrapped by another paraovarian cyst. Laparoscopic surgery is considered useful for diagnostic and therapeutic purposes and is, therefore, recommended owing to difficulty in differentiating paraovarian cysts from ovarian cysts.

16.
Clin Case Rep ; 10(2): e05320, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35140943

RESUMEN

This clinical image presents an unusual report of simultaneous laparoscopic resection of a hydrocele of the canal of Nuck and an ovarian tumor. Laparoscopic treatment with a proper approach is a useful technique in some cases.

17.
Clin Case Rep ; 10(2): e05420, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35154729

RESUMEN

This clinical image presents a report on the diagnosis and treatment of anti-NMDAR encephalitis, a rare disease. This report emphasizes the importance of a differential diagnosis for acute psychiatric symptoms. Accurate and timely diagnosis is critical for the selection and implementation of treatment and for optimal patient outcomes.

18.
Clin Calcium ; 21(9): 1335-46, 2011 Sep.
Artículo en Japonés | MEDLINE | ID: mdl-21881196

RESUMEN

Calcium transfer from the mother to the fetus and neonate during pregnancy and lactation plays an extremely important role in the bone health of the mother and infant. Calcium aids in bone health through all ages but is especially crucial during pregnancy and lactation. Despite facing similar demands for calcium in pregnancy and puerperium, the maternal adaptations differ significantly between these two reproductive periods. Although the studies are underway to establish the conclusion, the changes in the structure and metabolism of bone and calcium during pregnancy and the early stage of postpartum are evaluated by investigating bone mineral density (BMD) , bone histomorphometry and bone markers of human or animal models. The bone resorption increased at the end of pregnancy and lactation, and the bone formation increases and the bone structure is almost recovered after cessation of lactating in postpartum. Vitamin D and parathyroid hormone-related protein (PTHrP) status especially becomes crucial for optimal maternal and fetal outcomes, fetal and neonatal skeletal growth, and maternal health in later life.


Asunto(s)
Huesos/metabolismo , Calcio/metabolismo , Lactancia/metabolismo , Periodo Posparto/metabolismo , Animales , Transporte Biológico , Densidad Ósea , Desarrollo Óseo , Resorción Ósea , Calcio de la Dieta/administración & dosificación , Femenino , Humanos , Recién Nacido , Intercambio Materno-Fetal , Osteogénesis , Proteína Relacionada con la Hormona Paratiroidea/fisiología , Embarazo , Vitamina D/administración & dosificación , Vitamina D/fisiología
19.
Gan To Kagaku Ryoho ; 38(4): 689-92, 2011 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-21499007

RESUMEN

The subject was a 75-year-old female who was receiving paclitaxel and carboplatin(TC)chemotherapy every other week after surgery for ovarian cancer. She greatly complained of taste disorders after four cycles(of every other week administration) of TC chemotherapy. To understand how the taste disorder was caused by chemotherapy objectively, taste examinations were conducted for the patient in our department. These examinations were conducted after receiving the informed consent from the patient. The authors conducted taste examinations for the patient using serum zinc measurement, tongue cell culture, electrogustometry, and filter paper disc tests(before and after starting chemotherapy), and found that her serum zinc level fell significantly after four cycles of chemotherapy. Orally disintegrating tablets of polaprezinc were then administered to the patient, after which the subjective symptom of taste disorder improved. Her serum zinc level increased, and the electrogustometric threshold rapidly fell(an improvement). The filter paper disc test showed some improvement, particularly in the glossopharyngeal nerve and the greater petrosal nerve field.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carboplatino/efectos adversos , Carnosina/análogos & derivados , Compuestos Organometálicos/uso terapéutico , Neoplasias Ováricas/tratamiento farmacológico , Paclitaxel/efectos adversos , Trastornos del Gusto/prevención & control , Administración Oral , Anciano , Carboplatino/administración & dosificación , Carboplatino/uso terapéutico , Carnosina/uso terapéutico , Femenino , Humanos , Estadificación de Neoplasias , Neoplasias Ováricas/patología , Paclitaxel/administración & dosificación , Paclitaxel/uso terapéutico , Trastornos del Gusto/inducido químicamente , Compuestos de Zinc/uso terapéutico
20.
Clin Epidemiol ; 13: 237-244, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33790653

RESUMEN

PURPOSE: Although the validity of self-reported osteoporosis is often questioned, validation studies are lacking. This study was performed to investigate how well self-reported diagnoses of osteoporosis agreed with validated clinical information in young and middle-aged women in the Japan Nurses' Health Study (JNHS), a nationwide prospective cohort study of nursing professionals. PATIENTS AND METHODS: Data were reviewed for 15,717 subjects from the combined cohorts of the JNHS and a preceding pilot study (Gunma Nurses' Health Study). The subjects' mean age at the baseline (BL) survey was 41.6 ± 8.3 years, and the mean follow-up period was 11.5 ± 4.4 years. Participating nurses were mailed a follow-up questionnaire every 2 years. Respondents who self-reported a positive osteoporosis diagnosis during the study period were sent an additional confirmation questionnaire to corroborate the details. RESULTS: The number (proportion) of women with osteoporosis was 884 (5.6%) [primary osteoporosis, 812 (5.2%); secondary osteoporosis, 72 (0.5%)]. The cumulative incidence of osteoporosis at the age of 40, 50, 60, 70, and 80 years was estimated to be 0.1% (95% confidence interval, 0.1-0.2), 1.1% (0.9-1.3), 7.7% (7.0-8.4), 23.6% (21.6-25.7), and 54.2% (40.2-68.1), respectively. For BL and regular follow-up + expert review versus BL and regular follow-up + confirmation questionnaire + expert review, the positive predictive value (PPV) was 61.3% versus 85.6% and the negative predictive value (NPV) was 98.9% versus 98.2%, respectively. CONCLUSION: Self-reporting was associated with a high NPV for the incidence of osteoporosis. Although the PPV was slightly lower, additional corroborations by confirmation questionnaire might improve the PPV.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA